Towards Healthcare
Respiratory Disease Vaccine Market to Drive USD 98.41 Bn by 2035

Respiratory Disease Vaccine Market Sees Rapid Global Uptake

According to market projections, the global respiratory disease vaccine market, valued at USD 65.72 billion in 2025, is anticipated to reach USD 98.41 billion by 2035, growing at a CAGR of 4.12% over the next decade. The rising prevalence of respiratory diseases and advances in vaccine technology drive the respiratory disease vaccine market. North America dominated the global market due to a robust healthcare infrastructure and strong procurement budgets.

Content

  • Last Updated: 17 November 2025
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2023
  • Base Year: 2024
  • Estimated Years: 2025-2034

About The Author

Shivani Zoting is a dedicated research analyst specializing in the healthcare industry. With a strong academic foundation, a B.Sc. in Biotechnology and an MBA in Pharmabiotechnology, she brings a unique blend of scientific understanding and market strategy to her research.

Shivani contributes to Towards Healthcare and plays an active role at Precedence Research, where she focuses on delivering in-depth market intelligence, competitive analysis, and trend forecasting across pharmaceuticals, medical devices, digital health, and healthcare services. Her insights support healthcare companies, investors, and policymakers in making data-backed decisions in a highly regulated and rapidly evolving sector.

Additionally, Shivani collaborates with Statifacts, further expanding her healthcare domain reach by engaging in diverse projects across global markets. Her strength lies in transforming complex clinical and commercial data into strategic narratives that help stakeholders navigate the future of healthcare.

Talk to us
FAQ's

The respiratory disease vaccine market is valued at USD 68.43 billion in 2026 and is on track to reach USD 98.41 billion by 2035, witnessing a steady CAGR of 4.12% during the forecast span.

North America is leading the respiratory disease vaccine market due to the availability of state-of-the-art research and development facilities, the presence of key players, and a robust healthcare infrastructure.

The respiratory disease vaccine market includes 6 segments by target disease indication, by vaccine technology platform, by age group indication population, by route formulation, by end-user distribution channel, and by region.

Some key players include GSK, Merck, Sanofi, AstraZeneca, and Bharat Biotech.

Influenza, pneumococcal pneumonia, RSV, and Tdap are some of the vaccines for several respiratory diseases.

Seven different types of vaccines include inactivated, live attenuated, mRNA, recombinant, toxoid, and viral vector vaccines.

Centers for Disease Control and Prevention, National Health Service UK, UNICEF, Infectious Diseases Society of America, India Brand Equity Foundation, GOV.UK
Any Questions